Novel Nano-Based Drug Delivery Systems Targeting Hepatic Stellate Cells in the Fibrotic Liver

Devaraj Ezhilararasan,Thangavelu Lakshmi,Biond Raut

DOI: https://doi.org/10.1155/2021/4674046

IF: 3.791

2021-10-22

Journal of Nanomaterials

Abstract:Hepatic stellate cells (HSCs) exist in the liver’s perisinusoidal space, are phenotypically activated, and acquire myofibroblast-like phenotype. This phenotypic transformation is accountable for the accumulation and production of various extracellular matrix (ECM) proteins, involving different fibril-forming collagens in the perisinusoidal space, producing altered hepatic function and portal hypertension and increased vascular resistance, fibrosis, cirrhosis, and hepatocellular carcinoma. The activated HSCs/myofibroblasts are principal collagen-producing cells in the damaged liver. Therefore, fibrosis treatments are often targeting HSCs. HSCs store most of the total body’s retinol in their cytoplasm, and hence, antifibrotic nanomedicines are often targeted with vitamin A decoration. Vitamin A-decorated nanomedicines with siRNAs for transforming growth factor-beta, collagen, and connective tissue growth factors target to inhibit fibrogenesis and the ECM-associated gene expressions, leading to fibrosis regression. Similarly, a variety of miRNAs play pro- and antifibrotic function. In the fibrotic liver, the profibrotic miRNAs are targeted with their respective antagomir and the antifibrotic miRNAs are targeted with their respective agomirs along with HSC-specific nanodecoration. These miRNA treatments reduce fibrogenesis by downregulation of ECM-related gene expressions. However, liver fibrosis is caused by the upregulation of a different type of profibrotic signaling pathways associated with ECM accumulation in the fibrotic liver. Therefore, specific gene silencing by siRNAs or targeting particularly miRNA may also not effectively reduce fibrosis to a greater extent. However, nanodecoration of a drug is useful to deliver drugs into activated HSCs in the injured liver. Therefore, the aim of this review is to focus on targeted drug delivery towards activated HSCs in the persistently damaged liver.

materials science, multidisciplinary,nanoscience & nanotechnology

What problem does this paper attempt to address?

The problem this paper attempts to address is the design and application of targeted drug delivery systems for activated hepatic stellate cells (HSCs) in liver fibrosis. Specifically, the paper explores how to use nanotechnology to precisely deliver drugs to activated HSCs to inhibit the fibrosis process, reduce the accumulation of extracellular matrix (ECM), and ultimately reverse or alleviate liver fibrosis. The main focus points of the paper are as follows:

1. **The role of HSCs in liver fibrosis**:
- HSCs are activated after chronic liver injury and transform into a myofibroblast-like phenotype.
- Activated HSCs are responsible for producing and accumulating various ECM proteins, leading to liver dysfunction, portal hypertension, fibrosis, cirrhosis, and hepatocellular carcinoma.

2. **Existing therapeutic strategies**:
- Current anti-fibrotic treatments mainly focus on reducing the activation and proliferation of HSCs, promoting ECM degradation, inducing HSC apoptosis or senescence, and inhibiting oxidative stress.
- However, these methods face issues such as low bioavailability, poor solubility, non-specific targeting, and off-target effects.

3. **Application of nanotechnology**:
- Using vitamin A-modified nanoparticles, siRNA, and miRNA can enhance the targeting and delivery efficiency of drugs to activated HSCs.
- For example, vitamin A-modified nanoparticles can exploit the characteristic of HSCs storing large amounts of retinol to specifically deliver drugs to activated HSCs.
- siRNA and miRNA can interfere with the expression of specific genes to reduce ECM synthesis and the progression of fibrosis.

4. **Specific nano delivery systems**:
- The paper discusses the development of various nano delivery systems, including liposomes, polymer nanoparticles, gold nanoparticles, and silica nanoparticles.
- These systems can effectively deliver drugs, siRNA, and miRNA to activated HSCs, achieving anti-fibrotic effects.

5. **Future prospects**:
- Although current research has made some progress, many challenges remain, such as the systemic delivery of siRNA, long-term stability, and safety of drugs.
- Future research needs to further optimize the performance of nano delivery systems to improve their feasibility for clinical applications.

In summary, this paper aims to design and optimize targeted drug delivery systems for activated HSCs using nanotechnology, providing new ideas and methods for the treatment of liver fibrosis.